Citi lowered the firm’s price target on Cabaletta Bio (CABA) to $13 from $17 and keeps a Buy rating on the shares post the Q1 report. The company has received FDA alignment on a registrational trial design for rese-cel in myositis and now anticipates application submission for full approval in 2027, the analyst tells investors in a research note. With regulatory alignment in hand, Citi thinks Cabaletta is leading in the myositis CAR-T space and could be first to launch.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio’s Strong Financial Position and Strategic Clinical Progress Justify Buy Rating
- Cabaletta Bio price target raised to $25 from $23 at Guggenheim
- Cabaletta Bio Announces 2027 BLA Plans for Rese-cel
- Cabaletta Bio announces plans for anticipated 2027 rese-cel BLA submission
- Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue